Psyence Biomedical Ltd is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario and currently employs 12 full-time employees. The company went IPO on 2021-12-10. Psyence Biomedical Ltd is a multi-asset, vertically integrated biopharmaceutical company specializing in psychedelic-based therapeutics. The firm is focused on developing nature-derived (non-synthetic) psilocybin-based psychedelic medicine. The company is dedicated to addressing unmet mental health needs, particularly in palliative care. Its ongoing Phase IIb psilocybin clinical trial in Australia focuses on adjustment disorder in patients diagnosed with cancer.
PBM stock price ended at $2.96 on 水曜日, after dropping 6.92%
On the latest trading day Feb 11, 2026, the stock price of PBM fell by 6.92%, dropping from $3.19 to $2.96. During the session, the stock saw a volatility of 10.62%, with prices oscillating between a daily low of $2.92 and a high of $3.23. On the latest trading day, the trading volume for PBM rose by 14.8K shares, despite the declining prices. This uptick in volume may signal heightened risk in the near term. In total, 62.5K shares were traded, with a market value of approximately $5.5M.